Subscribe to RSS
DOI: 10.1055/a-2760-7548
Extent of Surgery in Lynch Syndrome Associated Colorectal Cancer and Endometrial Cancer Risk Reduction: Seeing the Forest for the Trees
Authors
Abstract
Lynch syndrome, the most common hereditary colorectal cancer syndrome, is caused by inherited pathogenic germline mutations in one of the mismatch repair genes. Beyond colorectal cancer risk, Lynch syndrome is a pan-cancer syndrome necessitating lifelong high-risk surveillance measures and/or risk-reducing surgical interventions. Patients with a diagnosis of colon cancer in the setting of Lynch syndrome have long faced the decision of pursuing extended surgical interventions for risk reduction versus limited segmental resections, with mismatch repair gene-specific cancer risks now helping to inform such decisions. Importantly, recent advances in the field, such as the remarkable efficacy of immunotherapy, the value and limitations of colonoscopy surveillance, and the increased utilization of cancer prevention methods, including the promise of vaccines, have made decisions regarding the optimal management of such patients even more complex. Although there is no one-size-fits-all answer, given the importance of such decisions on patients' quality of life, we advocate for shared and individualized decision-making that encompasses the patient's perspective as well as the expertise of surgeons and physicians across varied disciplines. Such decisions get more complicated when patients have to consider risk-reducing surgery for endometrial cancer in the absence of cancer as a prophylactic measure as well. Thus, informed discussion about the available surveillance and prevention armamentarium is the mainstay of achieving well-informed shared decisions in these cases.
Publication History
Article published online:
31 December 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Win AK, Jenkins MA, Dowty JG. et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2017; 26 (03) 404-412
- 2 Hampel H, Frankel WL, Martin E. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352 (18) 1851-1860
- 3 Park J, Karnati H, Rustgi SD, Hur C, Kong XF, Kastrinos F. Impact of population screening for lynch syndrome insights from the All of Us data. Nat Commun 2025; 16 (01) 523
- 4 Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34 (05) 424-425
- 5 Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116 (06) 1453-1456
- 6 Rodriguez-Bigas MA, Boland CR, Hamilton SR. et al. A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89 (23) 1758-1762
- 7 Umar A, Boland CR, Terdiman JP. et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96 (04) 261-268
- 8 Pearlman R, Frankel WL, Swanson BJ. et al. Prospective statewide study of universal screening for hereditary colorectal cancer: the Ohio colorectal cancer prevention initiative. JCO Precis Oncol 2021; 5: PO.20.00525
- 9 Esplin ED, Nielsen SM, Bristow SL. et al. Universal germline genetic testing for hereditary cancer syndromes in patients with solid tumor cancer. JCO Precis Oncol 2022; 6: e2100516
- 10 Cercek A, Foote MB, Rousseau B. et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 2025; 392 (23) 2297-2308
- 11 Kloor M, Huth C, Voigt AY. et al. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncol 2012; 13 (06) 598-606
- 12 Burn J, Sheth H, Elliott F. et al; CAPP2 Investigators. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 2020; 395 (10240): 1855-1863
- 13 Deng N, Reyes-Uribe L, Fahrmann JF. et al. Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in lynch syndrome. Clin Cancer Res 2023; 29 (21) 4361-4372
- 14 Chalabi M, Verschoor YL, Tan PB. et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med 2024; 390 (21) 1949-1958
- 15 Vogelstein B, Kinzler KW. The path to cancer –three strikes and you're out. N Engl J Med 2015; 373 (20) 1895-1898
- 16 Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the WNT pathway. Oncogene 2006; 25 (57) 7531-7537
- 17 Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci U S A 2002; 99 (12) 8265-8270
- 18 Engel C, Ahadova A, Seppälä TT. et al; German HNPCC Consortium, the Dutch Lynch Syndrome Collaborative Group, Finnish Lynch Syndrome Registry. Associations of pathogenic variants in MLH1, MSH2, and MSH6 with risk of colorectal adenomas and tumors and with somatic mutations in patients with lynch syndrome. Gastroenterology 2020; 158 (05) 1326-1333
- 19 Ahadova A, Gallon R, Gebert J. et al. Three molecular pathways model colorectal carcinogenesis in lynch syndrome. Int J Cancer 2018; 143 (01) 139-150
- 20 Latham A, Srinivasan P, Kemel Y. et al. Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J Clin Oncol 2019; 37 (04) 286-295
- 21 Hodan R, Gupta S, Weiss JM. et al. Genetic/familial high-risk assessment: colorectal, endometrial, and gastric, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2024; 22 (10) 695-711
- 22 Ten Broeke SW, van der Klift HM, Tops CMJ. et al. Cancer risks for PMS2-sssociated lynch syndrome. J Clin Oncol 2018; 36 (29) 2961-2968
- 23 Chouhan H, Abbass MA, Hrabe JE. et al. Evaluation of urinalysis-based screening for urothelial carcinoma in patients with lynch syndrome. Dis Colon Rectum 2022; 65 (01) 40-45
- 24 Parry S, Win AK, Parry B. et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60 (07) 950-957
- 25 Prospective Lynch Syndrome Database. Metachronous colorectal cancer risks after extended or segmental resection in MLH1, MSH2, and MSH6 Lynch syndrome: multicentre study from the prospective lynch syndrome database. Br J Surg 2025; 112 (04) znaf061
- 26 Win AK, Parry S, Parry B. et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 2013; 20 (06) 1829-1836
- 27 Kalady MF, Lipman J, McGannon E, Church JM. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. Ann Surg 2012; 255 (06) 1121-1125
- 28 You YN, Chua HK, Nelson H, Hassan I, Barnes SA, Harrington J. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. Dis Colon Rectum 2008; 51 (07) 1036-1043
- 29 Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP. et al. Quality of life after surgery for colon cancer in patients with lynch syndrome: partial versus subtotal colectomy. Dis Colon Rectum 2012; 55 (06) 653-659
- 30 Sun J, Dong M, Xiao X. Efficacy, functional outcome and post-operative complications of total abdominal colectomy with ileorectal anastomosis vs. segmental colectomy in hereditary non-polyposis colorectal cancer. Exp Ther Med 2018; 16 (03) 1603-1612
- 31 Le DT, Durham JN, Smith KN. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357 (6349) 409-413
- 32 André T, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383 (23) 2207-2218
- 33 Andre T, Elez E, Van Cutsem E. et al; CheckMate 8HW Investigators. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med 2024; 391 (21) 2014-2026
- 34 Cercek A, Lumish M, Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022; 386 (25) 2363-2376
- 35 Møller P, Seppälä T, Bernstein I. et al; Mallorca Group (http://mallorca-group.org). Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective lynch syndrome database. Gut 2017; 66 (09) 1657-1664
- 36 Eikenboom EL, Moen S, van Leerdam ME. et al; collaborative investigators from the Dutch Foundation for Detection of Hereditary Tumors. Metachronous colorectal cancer risk according to lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study. Lancet Gastroenterol Hepatol 2023; 8 (12) 1106-1117
- 37 Quezada-Diaz FF, Hameed I, von Mueffling A. et al. Risk of metachronous colorectal neoplasm after a segmental colectomy in lynch syndrome patients according to mismatch repair gene status. J Am Coll Surg 2020; 230 (04) 669-675
- 38 Singhal S, Riggs ED, Ruth KJ. et al. Uptake of aspirin chemoprevention in patients with lynch syndrome. JCO Precis Oncol 2024; 8: e2400562
- 39 Harrold EC, Foote MB, Rousseau B. et al. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade. Nat Med 2023; 29 (10) 2458-2463
- 40 Vilar E, Willis J, D'Alise M. et al. 638 Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy lynch syndrome carriers: results from phase Ib/II trial. J Immunother Cancer 2024; 12 (Suppl. 02) A732-A732
- 41 Bowen CM, Sinha KM, Vilar E. Current trends in vaccine development for hereditary colorectal cancer syndromes. Clin Colon Rectal Surg 2023; 37 (03) 146-156
- 42 Karamurzin Y, Soslow RA, Garg K. Histologic evaluation of prophylactic hysterectomy and oophorectomy in Lynch syndrome. Am J Surg Pathol 2013; 37 (04) 579-585
- 43 Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26 (32) 5284-5293
- 44 Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 2011; 42 (07) 918-931
- 45 Parker WH, Feskanich D, Broder MS. et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 2013; 121 (04) 709-716
- 46 Hibler EA, Kauderer J, Greene MH, Rodriguez GC, Alberts DS. Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause 2016; 23 (11) 1228-1232
- 47 Kotsopoulos J, Hall E, Finch A. et al. Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation. JAMA Netw Open 2019; 2 (08) e198420
- 48 Chan JL, Letourneau J, Salem W. et al. Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients. J Cancer Surviv 2017; 11 (01) 58-63
- 49 Niburski K, Guadagno E, Abbasgholizadeh-Rahimi S, Poenaru D. Shared decision making in surgery: a meta-analysis of existing literature. Patient 2020; 13 (06) 667-681
- 50 Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, Church JM. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg 2010; 252 (03) 507-511 , discussion 511–513
- 51 Van Dalen R, Church J, McGannon E, Fay S, Burke C, Clark B. Patterns of surgery in patients belonging to Amsterdam-positive families. Dis Colon Rectum 2003; 46 (05) 617-620
- 52 Cirillo L, Urso ED, Parrinello G. et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. Ann Surg 2013; 257 (05) 900-904
- 53 de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G. et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002; 45 (12) 1588-1594
- 54 Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with lynch syndrome. Dis Colon Rectum 2010; 53 (01) 77-82
- 55 Kim TJ, Kim ER, Hong SN. et al. Survival outcome and risk of metachronous colorectal cancer after surgery in lynch syndrome. Ann Surg Oncol 2017; 24 (04) 1085-1092
- 56 Stupart DA, Goldberg PA, Baigrie RJ, Algar U, Ramesar R. Surgery for colonic cancer in HNPCC: total vs segmental colectomy. Colorectal Dis 2011; 13 (12) 1395-1399
- 57 Anele CC, Adegbola SO, Askari A. et al. Risk of metachronous colorectal cancer following colectomy in lynch syndrome: a systematic review and meta-analysis. Colorectal Dis 2017; 19 (06) 528-536
- 58 Malik SS, Lythgoe MP, McPhail M, Monahan KJ. Metachronous colorectal cancer following segmental or extended colectomy in lynch syndrome: a systematic review and meta-analysis. Fam Cancer 2018; 17 (04) 557-564
- 59 Ko YS, Kim YS, Cho YB. et al. Functional outcome after colectomy in familial colorectal cancer: a comparison of segmental and total colectomy. Br J Surg 2011; 98 (02) 249-256
- 60 Zhang X, Wei Z, Chen H. et al. Efficacy, functional outcome and post-operative complications of segmental versus total abdominal colectomy in lynch syndrome patients. Exp Ther Med 2018; 15 (03) 2247-2256
